[{"innerBlocks":[],"name":"core\/freeform","postId":731,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"Cigna Ventures is leading a $23 million investment in GNS Healthcare, a specialized artificial intelligence company.

Cigna Ventures is a strategic corporate venture capital partner and wholly owned indirect subsidiary of Cigna.

Joining the funding round were Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, as well as former Caesar\u2019s CEO and Aetna Division President Gary Loveman. The investment will back GNS and Cigna\u2019s partnership to combine respective data, advanced analytics and machine learning to optimize Cigna\u2019s condition-specific clinical care programs, the companies said. Oncology will be the first area of focus.

\u201cWe are thrilled to have Cigna contribute to our next phase of growth,\u201d said Colin Hill, chairman, CEO and co-founder of GNS Healthcare. \u201cCigna is the perfect complement to our cadre of leading biopharma companies and health plan partners committed to improving patient outcomes through causal AI and the precision healthcare it enables.\u201d

GNS transforms massive and diverse data streams to precisely match therapeutics, procedures, and care management interventions to individuals, thus improving health outcomes and saving money, says GNS.

The GNS causal learning and simulation platform\u2014called REFS (Reverse Engineering and Forward Simulation)\u2014analyzes data sets beyond correlation, inferring causal mechanisms between variables to answer questions that include: \u201cHow will the patient respond to this treatment?\u201d and \u201cWhat if we choose one intervention over another?\u201d

Cigna and GNS contend that REFS is \u201cthe only commercially available platform that infers causal mechanisms from patient data at scale from traditional healthcare and emerging data sources to bring the promise of precision medicine within reach.\u201d

\u201cThe latest funding round will enable Cigna and others to deliver on increasing consumer demand for personalization in new and more effective ways,\u201d the companies said.

Cigna launched Cigna Ventures last September to back new and innovative business models across analytics, digital health, care delivery and care management. The funding of GNS is the first analytics-focused investment CV has announced since the fund launched, according to Cigna.

\u201cCigna is committed to improving the total health and well-being of our customers \u2013 and the personalized clinical care interventions that we expect GNS to facilitate will play a huge role in achieving those improvements,\u201d said Tom Richards, global lead of strategy and business development at Cigna. \u201cGNS aligns with our vision and together we can super-charge our advanced analytics capabilities and provide even deeper, more predictable insights that will further enhance customer access to the highest quality treatment and care, in the preferred and appropriate place, at the right time.\u201d
","saveContent":"Cigna Ventures is leading a $23 million investment in GNS Healthcare, a specialized artificial intelligence company.

Cigna Ventures is a strategic corporate venture capital partner and wholly owned indirect subsidiary of Cigna.

Joining the funding round were Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, as well as former Caesar\u2019s CEO and Aetna Division President Gary Loveman. The investment will back GNS and Cigna\u2019s partnership to combine respective data, advanced analytics and machine learning to optimize Cigna\u2019s condition-specific clinical care programs, the companies said. Oncology will be the first area of focus.

\u201cWe are thrilled to have Cigna contribute to our next phase of growth,\u201d said Colin Hill, chairman, CEO and co-founder of GNS Healthcare. \u201cCigna is the perfect complement to our cadre of leading biopharma companies and health plan partners committed to improving patient outcomes through causal AI and the precision healthcare it enables.\u201d

GNS transforms massive and diverse data streams to precisely match therapeutics, procedures, and care management interventions to individuals, thus improving health outcomes and saving money, says GNS.

The GNS causal learning and simulation platform\u2014called REFS (Reverse Engineering and Forward Simulation)\u2014analyzes data sets beyond correlation, inferring causal mechanisms between variables to answer questions that include: \u201cHow will the patient respond to this treatment?\u201d and \u201cWhat if we choose one intervention over another?\u201d

Cigna leads $23M investment in GNS Healthcare’s AI

More for you